Relapse of AML after hematopoietic stem cell transplantation: methods of monitoring and preventive strategies. A review from the ALWP of the EBMT
Relapse of AML after hematopoietic stem cell transplantation: methods of monitoring and preventive strategies. A review from the ALWP of the EBMT
复制标题
DOI：
10.1038/bmt.2016.167
复制
发表时间：
2016-11-01
影响因子：
4.8
通讯作者：
Nagler, A.
中科院分区：
文献类型：
--
作者：
Tsirigotis, P.;Byrne, M.;Nagler, A.
异基因造血干细胞移植（allo-SCT）仍然是通过移植物抗白血病效应介导的最有效的抗白血病活性的治疗方法。然而，很大一部分 AML 患者在异基因 SCT 后会复发。这些患者的预后很差，长期生存的可能性很大
Allogeneic hematopoietic stem cell transplantation (allo-SCT) remains the therapeutic method with the most potent anti-leukemic activity mediated by the graft versus leukemia effect. However, a significant proportion of patients with AML will relapse after allo-SCT. The prognosis for these patients is dismal, with a probability of long-term survival of